

Herpes Zoster Vaccination Update: Introduction

ACIP Meeting

June 20, 2018

Edward Belongia, MD

ACIP Chair, Zoster Working Group

Center for Clinical Epidemiology & Population Health

Marshfield Clinic Research Institute

2018 Herpes Zoster Work Group

ACIP Members	Edward Belongia, MD (Chair)	
	Kelly Moore	
	Grace Lee	
Ex Officio Members	Paula Agger, MD, MPH	FDA
	Jeffrey Cohen, MD	NIH
	Jeffrey Kelman, MD	CMS
Liaison Representatives	Jeffrey Duchin, MD	NACCHO
	Mary Pat Friedlander, MD	AAFP
	Adam Welch, PharmD	APhA
	William Schaffner, MD	NFID
	Kenneth Schmader, MD	AGS
	Sandra Fryhofer, MD	AMA/ACP
	Kathy Neuzil, MD, MPH	IDSA
	Mark Netoskie, MD, MBA	AHIP
	Lynn Bahta, RN, PHN	AIM

Invited Consultants
Robin Avery, MD
Al Benson, MD
Paul Cieslak, MD
Jeffrey Curtis, MD, MPH
Jay Fishman, MD
Samuel Katz, MD
Vicki Morrison, MD
Steven Pergam, MD
Lisa Prosser, PhD
CDC Liaison
Rafael Harpaz, MD
Kathleen Dooling, MD

In October 2017, the ACIP made the following recommendations:

- 1)** Recombinant zoster vaccine (RZV, [Shingrix]) is recommended for the prevention of herpes zoster and related complications for immunocompetent adults aged ≥ 50 years.
- 2)** RZV is recommended for the prevention of herpes zoster and related complications for immunocompetent adults who previously received zoster vaccine live (ZVL, [Zostavax]).
- 3)** RZV is preferred over ZVL for the prevention of herpes zoster and related complications.

CDC 2018 Herpes Zoster Policy Note recommendations serve as a supplement to the existing recommendations for the use of ZVL in immunocompetent adults aged ≥ 60 years.

Herpes Zoster WG Activities since Oct 2017

- Reviewed and approved Herpes Zoster MMWR Policy Note- *Recommendations of the ACIP for Use of Herpes zoster Vaccines* (published Jan 26, 2018)
- 9 Work Group meetings:
 - Burden and pathophysiology of herpes zoster in immunocompromised persons
 - Herpes zoster vaccine performance in immunocompromised
 - Post licensure monitoring of RZV
- Today's presentation is on the enhanced safety, effectiveness, and coverage to monitor the impact of the preferential recommendation

Acknowledgements

- **ACIP Herpes Zoster Work Group:** Edward Belongia, Paula Agger, Robin Avery, Lynn Bahta, Al Benson, Paul Cieslak, Jeff Cohen, Jeff Curtis, Kathleen Dooling, Jeff Duchin, Jay Fishman, Mary Pat Friedlander, Sandra Fryhofer, Sam Katz, Jeff Kelman, Vicki Morrison, Kelly Moore, Mark Netoskie, Kathy Neuzil, Steve Pergam, Lisa Prosser, Bill Schaffner, Ken Schmader, Adam Welch
- **Zoster Work Group Liaison:** Kathleen Dooling, Rafael Harpaz
- **CDC + other contributors:** Amanda Cohn, Shelly Deeks, Angela Guo, Theresa Harrington, Shainoor Ismail, Kathryn Ivy, David Kim, Andrew Kroger, Jessica Leung, Adriana Lopez, Mona Marin, Karen Mason, Susannah McKay, Ismael Ortega-Sanchez, Mark Pallansch, Manisha Patel, Candice Robinson, Jeanne Santoli, Tom Shimabukuro, Jeannette St. Pierre, Ray Strikas, Chengbin Wang, Richard Warrington, Cindy Weinbaum